The University of Texas MD Anderson Cancer Center and Myriad Genetics (MYGN) announced a five-year strategic alliance to accelerate the clinical evaluation and development of Myriad’s molecular ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback